GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Update

GT Biopharma, Inc. (NASDAQ:GTBP) was the target of a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 19,400 shares, a growth of 9.6% from the October 31st total of 17,700 shares. Approximately 1.0% of the company’s shares are sold short. Based on an average daily trading volume, of 18,600 shares, the short-interest ratio is currently 1.0 days.

Analyst Ratings Changes

A number of analysts have commented on the stock. Roth Capital raised shares of GT Biopharma to a “strong-buy” rating in a research report on Monday. Roth Mkm started coverage on GT Biopharma in a research report on Monday. They set a “buy” rating and a $11.00 target price on the stock.

GT Biopharma Stock Up 3.6 %

Shares of GTBP stock opened at $2.89 on Wednesday. The firm has a 50 day moving average of $2.68 and a 200-day moving average of $2.73. GT Biopharma has a 52 week low of $1.92 and a 52 week high of $10.66.

GT Biopharma Company Profile

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.